Sparkle Clean Tech Licenses Oil & Gas Water Treatment Technologies from Siemens Energy, Inc.
20.1.2025 12:03:00 CET | Business Wire | Press release
This License expands Sparkle's portfolio for sustainable, integrated water solutions that support oil and gas exploration and production and support customers' waste and efficiency goals.
Sparkle Clean Tech, a global provider of process technologies and value-driven energy solutions for upstream Oil and Gas customers, is pleased to announce that it has reached an agreement with Siemens Energy to license Intellectual Property from their upstream oil and gas related water solutions technology portfolio. The license includes technologies for primary, secondary and tertiary oily water treatment, such as Corrugated Plates, Hydrocyclones, Flotation Units, Walnut Shell filters, as well as regenerable membrane-based treatment technologies. This license includes intellectual property such as patents, copyrights and trade secrets. The technologies effectively address the water and wastewater needs of the oil and gas industry.
Sparkle Clean Tech will license Siemens Energy's Monosep™ Nutshell Filtration; Perfomedia™ adsorption technology; Veirsep™ and Spinsep™ Flotation with Brise DGF Pumps or Eductors; FoldedFlo™ DAF; Liquid/Liquid Hydro cyclones with TL1.05™ Liners; and Corrugated Plate separators, along with the associated intellectual property.
The integration of these technologies will expand Sparkle Clean Tech's portfolio of sustainable and integrated offerings into the treatment of water and wastewater produced in Oil & Gas exploration and production facilities.
Mike Foster, Director of Sparkle Clean Tech, stated, "Water and wastewater management in Oil & Gas exploration and production is critical for our customers who are looking for answers to improve efficiency, make their operations more sustainable, and comply with environmental regulations and standards. This license adds to our growing integrated technology portfolio and provides yet another sustainable solution for our customers."
Sumeet Mehra, CEO Sparkle Clean Tech, stated further "We are thrilled to announce the licence of Siemens Energy's oil and gas water and wastewater treatment technologies. This strategic move reinforces our commitment to providing comprehensive and sustainable solutions to our customers in the oil and gas industry. The addition of these cutting-edge technologies to our portfolio not only expands our capabilities but also strengthens our position as a leader in integrated water solutions. We are confident that these licenses will play a significant role in supporting our customers' waste and efficiency goals while contributing to the preservation of our environment."
The licensed portfolio of technologies focuses on the treatment of oil & gas wastewater from production wells, while the Brise & Perfomedia process offers an efficient wastewater treatment solution designed to remove pollutants from produced wastewater. Both processes offer significant advancements in waste management within the oil and gas industry.
Sparkle Clean Tech is committed to driving innovation and sustainability within the oil and gas sector. By licensing Siemens Energy's upstream water treatment technologies, Sparkle Clean Tech aims to offer comprehensive solutions that support customers' waste and efficiency goals, while also contributing to environmental preservation.
About Sparkle Clean Tech:
Sparkle Clean Tech is a global provider of process technologies and value-driven energy solutions for upstream Oil and Gas customers. With a focus on sustainability and innovation, Sparkle Clean Tech aims to optimize operations and support customers' environmental goals while driving efficiency and profitability.
Sparkle Clean Tech’s other solutions include treatment technologies for water and wastewater management. Utilizing specialized Ultrafiltration, Reverse Osmosis, Desalination, and High Purity Water technologies, Sparkle addresses the needs of diverse industries including Lithium, Microelectronics, Mining among others. With a global customer footprint, Sparkle has executed several projects in the Americas, Europe, Asia, and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120193068/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom